GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on Jun 27, 2025
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Midcap 150 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GlaxoSmithKline Pharmaceuticals announced that its 100th Annual General Meeting will be held on June 27, 2025, via video conferencing. The Board recommended a final dividend of Rs. 42 per share (up from Rs. 32 last year), with the record date set as May 30, 2025. For FY25, standalone revenue from operations grew about 9% to Rs. 3,723 crore, while net profit jumped roughly 57% to Rs. 919 crore, helped by the absence of the prior year's one-time VRS (Voluntary Retirement Scheme) charge. Profit before exceptional items and tax rose to Rs. 1,244 crore from Rs. 953 crore, with EBITDA margins expanding to about 35% from 30%. The company also re-appointed Dr. Sunita Maheshwari as Independent Director for a second three-year term and appointed Parikh & Associates as Secretarial Auditor for FY26–FY30. Statutory auditors Deloitte Haskins & Sells LLP issued an unmodified opinion on both the standalone and consolidated financial statements.
Higher dividend and strong profit growth reinforce shareholder returns, while the clean, unmodified auditor opinion and zero-debt, cash-rich balance sheet should support investor confidence. The sharp profit growth is partly flattered by the absence of last year's one-off VRS cost, so underlying like-for-like growth is more modest.